Agilent Technologies Inc.. (9/20/24). "Press Release: Agilent Completes Acquisition of Biovectra". Santa Clara, CA.

	Region	Canada
	Organisation	Agilent Technologies Inc. (NYSE: A)
	Organisation 2	Biovectra Inc. (CA)
	Product	contract manufacturing (drugs)
	Product 2	contract manufacturing (biologicals)
	Index term	Biovectra–Agilent: investment, 202407– acquisition of Biovectra for $925m by Agilent from H.I.G. Capital
	Person	McDonnell, Padraig (Agilent 202405– CEO before SVP + President CrossLab Group before EVP + GM LifeSAM EMEAI)
	Person 2	Litton, Sara (Agilent 202212 Media Relations)

Pharmaceutical customers will benefit from a broader set of specialized CDMO capabilities

Agilent Technologies Inc. (NYSE: A) today announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.

All closing conditions are completed, including receipt of regulatory approvals. BIOVECTRA is now part of Agilent’s Diagnostics and Genomics Group.

“We are delighted to officially welcome the BIOVECTRA team to Agilent,” said Agilent President and CEO Padraig McDonnell. “This acquisition demonstrates our commitment to providing customers the most advanced capabilities to accelerate their therapeutics programs, including best-in-class cGMP pharmaceutical manufacturing.”

With the addition of BIOVECTRA, Agilent will expand its portfolio of CDMO services, add rapidly growing modalities, and bring world-class capabilities to support gene editing. Additional details are available in the news release announcing the acquisition agreement.

Agilent expects the transaction will be $0.05 dilutive to non-GAAP earnings per share (EPS) in the first full year after closing and deliver a double-digit return on invested capital (ROIC) by year five. Agilent funded the transaction using a mix of cash on hand and debt financing.

Additional Information:

FAQs for customers

Highlights for Investors

About Agilent’s Oligonucleotide GMP Manufacturing

About BIOVECTRA

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom.

Follow Agilent on LinkedIn and Facebook.

Investor Contact

Parmeet Ahuja
+1 408-345-8948
parmeet_ahuja@agilent.com
Media Contact

Sarah Litton
+1 408-361-0405
sarah.litton@agilent.com

Record changed: 2025-01-14